Novartis ADR had its Relative Strength (RS) Rating upgraded from 66 to 71 Tuesday — a welcome improvement, but still short of the 80 or better score you prefer to see.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the best stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Novartis ADR can continue to show renewed price strength and hit that benchmark.
Novartis ADR is working on a flat base with a 124.83 entry. See if it can clear the breakout price in heavy trading.
While earnings growth decreased last quarter from 27% to 23%, revenue grew 15%, up from 12% in the previous report.
Novartis ADR earns the No. 3 rank among its peers in the Medical-Ethical Drugs industry group. Grifols ADR is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
